PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled …

FJ Raal, EA Stein, R Dufour, T Turner, F Civeira… - The Lancet, 2015 - thelancet.com
Background Heterozygous familial hypercholesterolaemia is characterised by low cellular
uptake of LDL cholesterol, increased plasma LDL cholesterol concentrations, and premature …
被引用次数：929 相关文章

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled …

FJ Raal, EA Stein, R Dufour, T Turner… - Lancet (London …, 2014 - europepmc.org
Background Heterozygous familial hypercholesterolaemia is characterised by low cellular
uptake of LDL cholesterol, increased plasma LDL cholesterol concentrations, and premature …

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled …

FJ Raal, EA Stein, R Dufour, T Turner, F Civeira… - The Lancet, 2015 - Elsevier
Background Heterozygous familial hypercholesterolaemia is characterised by low cellular
uptake of LDL cholesterol, increased plasma LDL cholesterol concentrations, and premature …

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled …

FJ Raal, EA Stein, R Dufour, T Turner, F Civeira… - The Lancet, 2015 - hal.science
BACKGROUND: Heterozygous familial hypercholesterolaemia is characterised by low
cellular uptake of LDL cholesterol, increased plasma LDL cholesterol concentrations, and …

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled …

FJ Raal, EA Stein, R Dufour, T Turner, F Civeira… - The Lancet, 2015 - thelancet.com
Background Heterozygous familial hypercholesterolaemia is characterised by low cellular
uptake of LDL cholesterol, increased plasma LDL cholesterol concentrations, and premature …

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled …

FJ Raal, EA Stein, R Dufour, T Turner, F Civeira… - The …, 2015 - wrap.warwick.ac.uk
ackground Heterozygous familial hypercholesterolaemia is characterised by low cellular
uptake of LDL cholesterol, increased plasma LDL cholesterol concentrations, and premature …

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled …

FJ Raal, EA Stein, R Dufour, T Turner, F Civeira… - The Lancet, 2015 - infona.pl
Heterozygous familial hypercholesterolaemia is characterised by low cellular uptake of LDL
cholesterol, increased plasma LDL cholesterol concentrations, and premature …

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled …

FJ Raal, EA Stein, R Dufour, T Turner, F Civeira… - The Lancet, 2015 - diva-portal.org
Background Heterozygous familial hypercholesterolaemia is characterised by low cellular
uptake of LDL cholesterol, increased plasma LDL cholesterol concentrations, and premature …
[PDF] redheracles.net

[PDF][PDF] PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo …

FJ Raal, EA Stein, R Dufour, T Turner, F Civeira… - Lancet, 2015 - redheracles.net
Background Heterozygous familial hypercholesterolaemia is characterised by low cellular
uptake of LDL cholesterol, increased plasma LDL cholesterol concentrations, and premature …

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled …

FJ Raal, EA Stein, R Dufour, T Turner, F Civeira… - Lancet, 2015 - kups.ub.uni-koeln.de
Background Heterozygous familial hypercholesterolaemia is characterised by low cellular
uptake of LDL cholesterol, increased plasma LDL cholesterol concentrations, and premature …